Clinical Trials

A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)


Study ID
Merck MK-3475-629

NCT Number
NCT03284424 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0611

Principle Investigator
Dr. Andrew Pecora

Phase
II

Sponsor
Merck


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now